Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?

SUMMARY Objective: To compare the metabolic effects of rosiglitazone, an antidiabetic agent of the thiazolidinedione class, in patients with type 2 diabetes with fair to moderate glycaemic control (glycosylated haemoglobin (HbA1c)  9%). Research design and methods: Data were pooled from two 26-week,...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2003, Vol.19 (3), p.192-199
Main Authors: Goldstein, Barry J., Cobitz, Alexander R., Hand, Linda M., Chen, Hongzi
Format: Article
Language:English
Subjects:
Beta-cell function
Biological and medical sciences
Blood Glucose - analysis
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Double-Blind Method
Glycaemic control
Glycated Hemoglobin A - analysis
Humans
Hypoglycemic Agents - pharmacology
Hypoglycemic Agents - therapeutic use
Insulin sensitivity
Medical sciences
Middle Aged
Rosiglitazone
Thiazoles - pharmacology
Thiazoles - therapeutic use
Thiazolidinediones
Type
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SUMMARY Objective: To compare the metabolic effects of rosiglitazone, an antidiabetic agent of the thiazolidinedione class, in patients with type 2 diabetes with fair to moderate glycaemic control (glycosylated haemoglobin (HbA1c)  9%). Research design and methods: Data were pooled from two 26-week, randomised, placebo-controlled, double-blind studies of rosiglitazone (4 and 8 mg/day). Results: After 26 weeks of treatment, HbA1c was significantly reduced (p 9%. After 26 weeks of treatment, reductions in fasting plasma glucose (FPG) were significant (p 
ISSN:0300-7995
1473-4877
DOI:10.1185/030079903125001695